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http:WHAT THIS PAPER ADDS
This is, to the author’s knowledge, the ﬁrst study that examines the inﬂuence of time to revascularization on
outcome of ischemic foot ulcers in patients with diabetes. This study observed consecutively presenting and
prospectively followed patients with diabetes, foot ulcers, and severe PAD, treated and followed by a multi-
disciplinary foot team. Shorter time to revascularization and less tissue destruction positively affects the
probability of healing over time of ischemic foot ulcer in patients with diabetes. The present study highlights the
need to prioritize investigation and revascularization in patients with diabetes and peripheral ischemia to
improve the outcome of foot ulcer.Objectives: There is limited information about whether time from recognition of decreased perfusion to
revascularization affects the probability of healing in a patient with a diabetic foot ulcer. The aim of the present
study was to examine whether time to revascularization after referral to a multidisciplinary foot center was
related to the outcome of foot ulcers in patients with diabetes and severe peripheral arterial disease (PAD).
Methods: Patients with diabetes, a foot ulcer, and a systolic toe pressure <45 mmHg or an ankle pressure
<80 mmHg were prospectively included at the foot center, and considered for revascularization according to a
preset protocol. All patients underwent invasive revascularization, either percutaneous transluminal angioplasty
(PTA) or reconstructive vascular surgery. All patients had continuous follow-up until healing or death irrespective
of the type of revascularization.
Results: A total of 478 patients were included (age 74 [range 66e80] years, 60% males), of whom 315 patients
(66%) had PTA, and 163 (34%) had reconstructive surgery. Of the 478 patients, 217 (45%) healed primarily, 88
(19%) healed after a minor amputation, 76 (16%) healed after a major amputation and 92 patients (19%) died
unhealed. The median time from inclusion in the study to revascularization was 8 weeks (3e18 weeks). Time to
vascular intervention within 8 weeks (p < .001), maximum Wagner grade reached <3 (p < .001), absence of
peripheral edema (p ¼ .033), and presence of intermittent claudication (p ¼ .001) were related to a higher
probability of healing.
Conclusions: Time to revascularization and extent of tissue damage were related to the probability of healing of
ischemic foot ulcer in patients with diabetes over time. In the presence of a decreased perfusion in a patient with
diabetes and a foot ulcer not only revascularization per se but also timing of revascularization is important for the
possibility of healing without a major amputation.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2014.06.041high as 25%.1,2 Foot ulcer in patients with diabetes is
associated with an increased risk of lower limb amputation,
and thus the primary aim of treatment for ischemic foot
ulcer is limb preservation.3 A coordinated healthcare system
with a multidisciplinary approach is essential to reduce the
number of amputations.4 Development of diabetic foot ul-
cer (DFU) is attributed to many interacting factors, the most
common ones being peripheral neuropathy and peripheral
arterial disease (PAD).3 PAD is an important precipitating
factor in the outcome of diabetic foot ulcer, as 50% of
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considered as the most important factor related to the
outcome of diabetic foot ulcer.3,7e9
Invasive revascularization, including open reconstructive
surgery and/or endovascular intervention, is the most
effective treatment that may improve peripheral circulation
and remedy symptoms.8 The majority of studies on revas-
cularization in ischemic conditions include both patients
with and without diabetes and examines the rate of limb
salvage improvement, rather than ulcer healing as an
outcome after a speciﬁc intervention.10e12
We have previously shown that invasive revascularization
positively affects the probability of healing of ischemic foot
ulcer in patients with diabetes.13 It is suggested that
vascular imaging and subsequent revascularization be
considered in patients with diabetes and ischemic foot ulcer
if no healing has occurred within 6 weeks of appropriate
non-invasive treatment irrespective of non-invasive vascular
test results.14 However, there is very limited information
regarding effect of waiting time to revascularization on the
outcome of diabetic foot ulcer. The aim of this study was to
examine the relationship between time to revascularization
and the probability of healing without major amputation in
consecutively presenting patients with diabetes and
ischemic foot ulcer, referred to a diabetic foot center.
MATERIAL AND METHODS
Study population
A total of 1,151 consecutively presenting patients with
diabetes and ischemic foot ulcer were admitted to a
multidisciplinary foot center during the years 1984e2006.
Out of these patients, 478 had either percutaneous trans-
luminal angioplasty (PTA) or reconstructive surgery, and
were included in the present study. The patients’ data were
prospectively recorded. Patients who did not have an
invasive revascularization were excluded. The reasons why
no invasive revascularization was done in excluded patients
have been described previously.15 The study was approved
by the local ethics committee.Inclusion criteria
Patients with diabetes mellitus, foot ulcer (Wagner grade
1e5, at or below the ankle) and a systolic toe pressure
<45 mmHg and/or systolic ankle pressure <80 mmHg were
included. When pressures could not be recorded, patients
with non-palpable foot pulses with an ulcer Wagner grade
4e5 or pain at rest were included. Rest pain was deﬁned as
severe persistent pain localized to the foot and relieved by
dependency. All patients were Fontaine grade 4.16Study design
Patients were followed and treated according to a preset
standardized protocol by a multidisciplinary team both in
and out of hospital until healing, with or without amputa-
tion, was achieved, or until the patient died with an un-
healed ulcer.13,15 A more detailed description ofmanagement protocols during study period including pro-
tocols on local wound treatment is available in the
Supplementary Information (online only). All lesions were
assessed and documented by the same team. Outpatient
treatment was carried out in collaboration with primary
healthcare and home nursing services. Physical examination
of the foot was performed at inclusion and regularly during
the study by the multidisciplinary team.
The core team consisted of a diabetologist, an orthopedic
surgeon, an orthotist, a podiatrist, and a registered nurse
educated in diabetes. Systolic toe and ankle blood pressure
was measured using strain gauge and Doppler techniques at
the vascular laboratory.17 Radiological arterial investigation
was carried out according to a prescheduled program by a
vascular surgeon integrated in the team on a regular basis.
Specially trained casting technicians provided a continuous
service for total contact casting. A specialist in infectious
diseases was available for consultations when required.
At entry to the study data were collected on previous
management, referral, patient characteristics, co-
morbidities, ulcer characteristics and laboratory
investigations.13
Each patient was represented by one lesion below the
ankle. Patients with two or more concurrent lesions were
represented by the one with the worst outcome. Patients
with three or more ulcers on the same foot were classiﬁed
as having multiple ulcers. The most superﬁcial ulcer
included was a full thickness skin ulcer penetrating into the
subcutaneous layer. The Wagner grade at inclusion and the
maximal Wagner grade reached were recorded. Minor
amputation is deﬁned as amputation through or below the
ankle joint; and major amputation is deﬁned as amputation
above the ankle joint.18Vascular intervention
Angiography was performed at the discretion of a vascular
surgeon according to a written program that was jointly
agreed upon. A retrograde aorto-femoral angiogram,
routinely visualizing the distal vessels including the pedal
arch, was performed if the medical condition allowed and
subject to informed consent. The catheter was placed as
distal as possible and delayed and magniﬁed lateral foot
views were routinely obtained. The popliteal and crural
arteries were selectively catheterized when possible. All
patients undergoing angiography were treated according
to a program prior to and after intervention with respect
to hydration and choice of pharmaceutical drugs to avoid
renal failure.19 The decision for revascularization was
taken by the vascular surgeon at the weekly interdisci-
plinary diabetic foot round, mainly based on the ulcer
characteristics, ﬁndings of peripheral pressure measure-
ments, and the response to the given conservative
management.20
Simultaneous PTA was performed when possible. In case
of stenoses or occlusions of more than one crural artery,
revascularization of all stenosed or occluded crural arteries
was attempted. The decision and performance of
442 T. Elgzyri et al.revascularization by vascular surgeon was based on its
technical availability and thus not necessarily directed to
the artery/arteries supplying the angiosome or ulcer area.
After PTA patients were put on low molecular weight
heparin for a minimum of three months.21 All patients were
treated with acetylsalicylic acid (ASA) or clopidogrel if no
contraindication was present.
In patients where PTA was not possible or not successful,
reconstructive surgery was considered and performed at
the discretion of the vascular surgeon, provided the pa-
tient’s medical condition allowed surgery and subject to
informed consent. Distal reconstructive surgery was deﬁned
as bypass to or distal to the tibioperoneal trunk. Post-
operative care and follow up were performed in coopera-
tion with and under the supervision of the team according
to program. Time to revascularization was calculated from
ﬁrst presentation at the diabetic foot center, since the time
from onset of ulcer was often unknown.Statistical analysis
Values are given as median and interquartile range (IQR,
25th to 75th). Comparisons between groups were made
using the ManneWhitney or chi-square test. Statistical
signiﬁcance was deﬁned as p< .05. Cox proportional hazard
regression (backward stepwise, lr, method) was used to
estimate the independent effect of waiting time to invasive
vascular intervention on time to ulcer healing. Time to
revascularization from arrival to the clinic was entered as a
categorical variable (1  8 weeks, 2 > 8 weeks). All vari-
ables in ManneWhitney or chi-square test with p < .15Table 1. Clinical characteristics at inclusion.
All (n ¼ 475)a Patients healed wi
major amputationb
Males 60% (284) 60% (184)
Age (yrs) 74 (66e80) 72 (65e79)
Age at diagnosis (yrs) 58 (44e67) 57 (43e67)
Diabetes duration (yrs) 15 (10e24) 15 (9e25)
HbA1c (%) 7.8 (6.2e9.0) 7.8 (6.1e9.0)
Serum creatinine (mmol/L) 92 (75e127) 90 (74e120)
Systolic BP (mmHg) 160 (140e170) 160 (140e175)
Ankle pressure (mmHg) 80 (60e110) 80 (60e110)
Toe pressure (mmHg) 30 (20e40) 30 (20e40)
Retinopathy 51% (242) 52% (159)
Nephropathy 38% (180) 35% (108)
Intermittent claudication 34% (162) 39% (120)
Rest pain 63% (299) 61% (187)
Peripheral edema 57% (270) 54% (164)
IHD 41% (196) 38% (117)
CHF 27% (127) 22% (66)
CVD 28% (131) 27% (82)
Wagner grade 3c 21% (98) 22% (68)
Max. Wagner grade 3d 55% (262) 48% (146)
Note. Data are % (n), or median (interquartile range). IHD¼ ischemic he
disease.
a Three drop-out patients are not included.
b Patients with primary healing of ulcer or healing after a minor ampu
c Ulcer Wagner grade at inclusion.
d Maximal ulcer Wagner grade reached during the study period.(Table 1) were included in analysis as covariates. The anal-
ysis was adjusted for the type of invasive vascular inter-
vention and for the study inclusion period (1, 1984e1989;
2, 1990e1999; 3, 2000e2006). Patients in the reconstruc-
tion surgery group (n ¼ 15) who had exploration only were
excluded from this analysis.
Univariate survival analysis of the statistically signiﬁcant
variables in the previous model was done using Kaplane
Meier analysis where statistical signiﬁcance was determined
by log-rank test. Statistical analysis was performed using
SPSS statistics 21.0 (IBM corporation, New York, NY, USA).RESULTS
General characteristics
Four hundred and seventy-eight patients were included.
Three patients dropped out following the revascularization,
and 475 continued follow up in the study. The median age
was 74 years (66e80 years); 60% were men, with a median
time of known diabetes of 15 years (10e24 years) (Table 1).
Intermittent claudication was present in 34% of patients,
rest pain in 63%, and peripheral edema in 57%. A systolic
toe pressure <45 mmHg and an ankle pressure <80 mmHg
were seen in 78% and 43% of patients respectively. At in-
clusion, 21% of the patients had deep ulcer of Wagner
grade 3, but 50% of the patients showed ulcer progres-
sion during follow up and 55% had reached a maximum
Wagner grade of 3 at some stage during the study period.
Median follow up time until outcome was 10 months (5e16
months).thout
(n ¼ 305)
Patients healed after major amputation
or deceased unhealed (n ¼ 170)
p
59% (101) .846
76 (70e80) .007
60 (49e68) .119
15 (10e23) .929
7.9 (6.4e9.0) .879
95 (78e148) .016
160 (140e170) .548
80 (60e111) .968
30 (20e40) .821
49% (83) .502
42% (72) .200
25% (42) .001
66% (113) .319
63% (107) .080
47% (80) .081
36% (62) .001
29% (50) .595
18% (30) .239
68% (116) <.001
art disease; CHF ¼ congestive heart failure; CVD ¼ cerebrovascular
tation.
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PTA was performed in 315 patients (66%). The levels of
interventions were at the iliac artery (10%), femoral artery
(53%), popliteal artery (35%), and at the crural arteries in
46% of cases, with an average of 1.5 procedures per ex-
tremity. Reconstructive vascular surgery was attempted in
163 patients (34%). In 15 (9%) an exploration revealed that
no reconstruction was possible. In the remaining 148 pa-
tients, 62% (n ¼ 92) had distal procedures, tibioperoneal
trunk or below (Supplemental Table). No difference was
found between patients who had PTA or reconstructive
surgery regarding ulcer progression (data not shown).Figure 1. Probability of ulcer healing without major amputation in
relation to time to revascularization.Time to revascularization
Median time from ﬁrst presentation at the diabetic foot
center to revascularization was 8 weeks (3e18 weeks).
Patients who had shorter time to revascularization (8
weeks) than those with longer time to revascularization (>8
weeks) had more often peripheral edema (62% vs. 50%,
p ¼ .025) and more often rest pain (69% vs. 56%, p ¼ .005).
Median time between diagnostic angiography and PTA was
0 week (0e0.1 week), while median time between diag-
nostic angiography and reconstructive surgery was 4 weeks
(2e10 weeks).Outcome
Of the 475 patients, 305 (64%) healed without major
amputation, 217 (45%) healed primarily, and 88 (19%)
healed after a minor amputation. Sixteen percent of the
patients healed after a major amputation (n ¼ 76) and 19%
(n ¼ 92) died unhealed. Two patients had an ongoing ulcer
at the end of follow up. Thus 80% of the surviving patients
healed without major amputation. The median healing time
irrespective of intervention was 10 (5e16) months. Median
healing time for primary healing was 8 (4e15) months, and
for healing after minor amputation was 14 (9e20) months.
Patients who healed without major amputation were
younger (p ¼ .007), had lower serum creatinine (p ¼ .016),
congestive heart failure less frequently (p ¼ .001), signs of
ulcer progression less often (p < .001), and intermittent
claudication more often (p ¼ .001) (Table 1).Figure 2. Probability of ulcer healing without major amputation in
relation to maximal tissue destruction reached during follow-up.Factors affecting probability of healing over time
Shorter time to revascularization (Fig. 1), Wagner grade <3
reached during follow-up period (Fig. 2), and presence of
intermittent claudication were signiﬁcantly related to higher
probability of healing without major amputation over time.
The presence of peripheral edema was signiﬁcantly related
to a lower probability of healing (Table 2). No statistical
differences were seen between patients with and without
intermittent claudication regarding toe pressure or ankle
pressure. However, patients with intermittent claudication
less often had peripheral edema compared with those
without intermittent claudication (49% vs. 62%, p ¼ .008).
Univariate survival analysis of each of these factors was
done using KaplaneMeier analysis. Each factor, time tovascular intervention (p < .001), maximal Wagner grade <3
(p < .001), absence of peripheral edema (p ¼ .013), and
intermittent claudication (p < .001), showed signiﬁcant
relation to healing without major amputation over time.
KaplaneMeier analysis was done for time to revasculari-
zation in patients who had reconstructive vascular surgery
or PTA separately. Both groups showed signiﬁcant relation
to healing without major amputation over time (Fig. 3A,B).
A similar analysis was done separately for time to revas-
cularization for patients who healed primarily and for those
Table 2. Survival analysis for factors affecting healing probability.
HR (95% CI) p
Intermittent claudication 1.64 (1.26e2.13) <.001
Peripheral edema 0.76 (0.58e0.98) .033
Max. Wagner grades <3 reached 1.92 (1.50e2.50) <.001
Time to intervention 8 weeksa 1.96 (1.52e2.52) <.001
Note. Healing is primary healing or healing after a minor
amputation. HR ¼ hazard ratio; CI ¼ conﬁdence interval.
a Time between ﬁrst presentation at diabetic centre and
revascularization.
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zation showed a statistically signiﬁcant relation to both
healing primarily (p ¼ .006), and to healing after minor
amputation (p < .001). KaplaneMeier analysis was done for
maximal Wagner grade in patients who had reconstructive
vascular surgery or PTA separately. Both groups showed
signiﬁcant relation to healing without major amputation
over time (Supplementary Fig. A,B).
DISCUSSION
In this study of consecutively presenting and prospectively
followed patients with diabetes, foot ulcers and severe PAD,
treated and followed by a multidisciplinary foot team, time
to revascularization, extent of tissue destruction, peripheral
edema, and intermittent claudication were related to the
probability of healing without major amputation.
This is, to the author’s knowledge, the ﬁrst study that
examines the inﬂuence of time to revascularization on
outcome of ischemic foot ulcer in patients with diabetes.
No difference was seen between patients who had endo-
vascular or open revascularization with regard to time to
revascularization after ﬁrst visit to the diabetic foot team.
In the present study, a shorter time from ﬁrst presenta-
tion at the foot team to revascularization, predicted a better
healing probability without major amputation. The ﬁnding
was the same for PTA and for reconstructive surgery.
Currently, an observation time of 4e6 weeks is recom-
mended by the International Working Group on the diabetic
foot before revascularization is considered in patients withFigure 3. Probability of ulcer healing without major amputation in re
structive vascular surgery or (B) percutaneous transluminal angioplastdiabetes and ischemic foot ulcer, irrespective of the results
of the non-invasive vascular tests.14 The European Society
for Vascular Surgery recommends local debridement in the
situation of deep foot infection, before considering revas-
cularization in the same patient group.7 Similarly, in the
Trans-Atlantic Inter-Society Consensus for the Management
of Peripheral Arterial Disease (TASC II), revascularization
should be considered if clear signs of critical limb ischemia
are present or if healing does not occur despite optimal
non-invasive treatment.8
There is limited information regarding the outcome of
revascularization in patients with diabetes, severe PAD, and
a foot ulcer. Most studies include patients with and without
diabetes and also report on outcome in term of limb
salvage rather than ulcer healing.12 In one study by Faglia E
et al.,22 regarding early debridement and revascularization
in patients with diabetes and an acute deep foot infection,
the authors concluded that immediate revascularization
allows for an outcome similar to patients without PAD. All
patients in that study had a deep foot infection, which was
the primary reason for the admission. It was concluded that
early surgery with regard to foot infection had a better
outcome than clinical observation using systemic antibi-
otics. The average time difference to revascularization for
the immediate versus later revascularization groups was
only 6 days.22
In the present study, the extent of tissue destruction
reached during follow up predicts worse healing over time.
Similar ﬁndings have recently been shown among patients
with diabetes and ischemic foot ulcer not available for
revascularization.15 This is in agreement with previous ob-
servations.6,23,24 This result per se, in addition to the ﬁnding
that time to revascularization affects outcome, may reﬂect
the need to consider invasive revascularization as early as
possible in patients with diabetes and ischemic foot ulcer
irrespective of the presence of pain or the extent of wound
and tissue destruction.
The presence of peripheral edema in this study was
signiﬁcantly related to a lower probability of healing. Pe-
ripheral edema has previously been shown to be related tolation to time to revascularization in patients who had (A) recon-
y.
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edema was also found to be more common in patients with
diabetes and foot ulcer who required amputation or died
unhealed than in those with primary healing.6,24e26 Edema
is often multifactorial in origin, and its treatment should
also focus on the predisposing cause.
Assessment of the need for revascularization in patients
with ischemic diabetic foot ulcers has frequently been
based on the presence of persisting ischemic pain, or when
healing probability is low by conservative treatment only.27
The fact that almost all patients in the present study un-
derwent revascularization, except for the 15 patients who
only had exploration, bias the results toward the high
prevalence of ischemic pain (97%), which indicates the
importance of ischemic symptoms in decision-making by
the vascular surgeon regarding revascularization and time
for intervention. Intermittent claudication, as a sign of pe-
ripheral ischemia, is known to be generally less frequent in
patients with diabetes than in those without it.13,25,28
Time to revascularization in this study was calculated
from ﬁrst visit to the foot team, since time from foot ulcer
onset is usually unknown or not conﬁrmed. Delay between
the onset of a foot lesion and ﬁrst treatment is common.
Almost 40% of foot lesions are not detected by the patient
him/herself but by relatives or healthcare staff.29 Further-
more, patients with diabetes who believe that pain is a
reliable symptom of foot ulceration are less likely to seek
medical advice early for foot care.30 The delay between
initial treatment of foot ulcer and referral to a foot clinic is
also common, where the main reasons are underestimation
of the severity of foot lesions or lack of recognition of
ischemia.31 There is still limited information regarding fac-
tors inﬂuencing the patient’s willingness to attend medical
care and regarding time delay in referral patterns and
pathways to intervention, particularly in patients with dia-
betes and ischemic foot ulcers.32 In the Eurodial study, an
ulcer duration of 1 week to 3 months was reported in 57%
of the patients and >3 months in 27%.9 Long ulcer duration
was associated with the risk of non-healing. However, ulcer
duration was reported as at entry into the study. In a large
Swedish study, Gershater et al.6 reported an estimation of
ulcer duration of 11 weeks (range 0e350 weeks), which had
no signiﬁcant effect on ulcer outcome.
Some methodological issues need to be considered when
evaluating the present cohort study. A potential negative
selection bias has to be taken into account, because the
patients were admitted to a university-based foot center,
and no exceptions were made with regard to age, co-
morbidity, or expected survival, and it cannot be excluded
that a few patients with foot ulcer were treated in other
healthcare units without the foot team’s knowledge. The
present study is based on a pre-deﬁned protocol regarding
inclusion, evaluation, and follow up. However, the decision
for vascular intervention was at the discretion of the
vascular surgeon. In the present study, the outcome after
PTA was not compared with that of vascular surgery, since
according to the design of the study, PTA was performed as
an initial choice of treatment, and vascular surgery wasperformed in patients not considered suitable for PTA. It
should also be recognized that recruitment to the present
study was stopped when magnetic resonance angiography
and computed tomography angiography became routine
procedures and even more extensive endovascular tech-
niques were introduced.
In conclusion, shorter time to revascularization and less
tissue destruction positively affects the probability of
healing of ischemic foot ulcer in patients with diabetes over
time. The present study highlights the need to prioritize
investigation and revascularization in patients with diabetes
and severe peripheral ischemia to improve the outcome of
foot ulcer.
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